Zobrazeno 1 - 10
of 29
pro vyhledávání: '"D. Weyandt"'
Autor:
Michael O. Harhay, PhD, Alessandro Gasparini, PhD, Allan J. Walkey, MD, MS, Gary E. Weissman, MD, MSHP, Michael J. Crowther, PhD, Sarah J. Ratcliffe, PhD, James A. Russell, MD, on behalf of the Vasopressin and Septic Shock Trial (VASST) Investigators, J. A. Russell, K. R. Walley, C. L. Holmes Boulton, J. T. Granton, P. C. Hebert, D. J. Cooper, S. Mehta, J. Singer, A. C. Gordon, M. M. Storms, S. Jones, G. R. Bernard, A. S. Slutsky, G. A. Wells, A. Gasparini, B. Savage, D. Ayers, R. Woods, K. Wu, M. Maralit, L. Smith, K. Foley, A. Suri, M. Steinberg, B. Howe, P. Galt, A. Higgins, M. E. LeBlanc, A. M. Sutherland, A. Sham, A. McLeod, D. R. Dorscheid, M. Hameed, L. Lazosky, S. Helderweirt, C. Honeyman, T. Terins, D. Chittock, J. Ronco, S. Logie, G. Wood, F. Auld, V. Stedham, M. Mantle, L. Fox, G. D. McCauley, J. D. Rolf, C. Erbacher, G. Martinka, S. Goulding, S. Silverwood, L. Leung, S. Keenan, J. Murray, M. Van Osch, B. Light, M. Dominique, P. Gray, R. Stimpson, S. Rosser, D. Bell, W. Janz, T. McArdle, I. Watpool, A. Matte-Martyn, D. J Cook, E. McDonald, F. Clarke, A. Tkaczyk, N. Zytaruk, T. Stewart, C. Martinez-Motta, R. MacDonald, V. Sivanantham, R. Hodder, J. Foxall, M. Lewis, M. Ward, C. Dos Santos, J. Friedrich, D. Scales, O. Smith, I. DeCampos, A. Richards, H. Michalopoulos, U. Bakshi, W. Sibbald, T. Smith, K. Code, B. Bojilov, C. Dale, M. Keogh, M. Meade, L. Hand, C. Martin, J. Kehoe, V. Binns, M. McGuire, G. Poirier, L. Provost, J. Muscedere, C. Diemer, V. Pellegrino, A. Hilton, S. Morrison, C. Weatherburn, K. Moulden, C. Harry, J. J. Presneill, M. S Robertson, J. F. Cade, B. D. Howe, D. K. Barge, C. A. Boyce, F. Healy, C. Wright, D. Weyandt, J. Barrett, C. Walker, S. Burton, G. Dobb, S. Perryman, J. Chamberlain, L. Thomas, A. Bersten, L. Daly, T. Hunt, D. Wood, B. Patel, J. Larson, M. Rady, G. LeBrun, E. Boyd, R. Rush
Publikováno v:
Critical Care Explorations, Vol 2, Iss 4, p e0104 (2020)
Objectives:. Non-mortality septic shock outcomes (e.g., Sequential Organ Failure Assessment score) are important clinical endpoints in pivotal sepsis trials. However, comparisons of observed longitudinal non-mortality outcomes between study groups ca
Externí odkaz:
https://doaj.org/article/2056019742ec46f58eab1b0a39ae1800
Publikováno v:
PLoS ONE, Vol 11, Iss 12, p e0167205 (2016)
The gene KRAS is commonly mutated in lung cancer to encode a constitutively active and oncogenic protein that is well established to initiate and maintain lung tumorigenesis. However, the remaining wild-type KRAS protein, or the other family members
Externí odkaz:
https://doaj.org/article/1950c509bf3e426d9cc61021ce7875cc
Autor:
Jamie D Weyandt, Benjamin L Lampson, Sherry Tang, Matthew Mastrodomenico, Diana M Cardona, Christopher M Counter
Publikováno v:
PLoS ONE, Vol 10, Iss 10, p e0140253 (2015)
Oncogenic, activating mutations in KRAS initiate pancreatic cancer. There are, however, two other Ras family members, Nras and Hras, which can be activated in the presence of oncogenic Kras. The role of these wild-type Ras proteins in cancer remains
Externí odkaz:
https://doaj.org/article/783c7146ac1a429089962cbbbdc37118
Publikováno v:
American Society of Clinical Oncology Educational Book. :825-832
Otto Warburg’s discovery in the 1920s that tumor cells took up more glucose and produced more lactate than normal cells provided the first clues that cancer cells reprogrammed their metabolism. For many years, however, it was unclear as to whether
Publikováno v:
PLoS ONE
PLoS ONE, Vol 11, Iss 12, p e0167205 (2016)
PLoS ONE, Vol 11, Iss 12, p e0167205 (2016)
The gene KRAS is commonly mutated in lung cancer to encode a constitutively active and oncogenic protein that is well established to initiate and maintain lung tumorigenesis. However, the remaining wild-type KRAS protein, or the other family members
Publikováno v:
Molecular cancer research : MCR. 14(7)
The renal cell carcinomas (RCC), clear cell, papillary, and chromophobe, have recently undergone an unmatched genomic characterization by The Cancer Genome Atlas. This analysis has revealed new insights into each of these malignancies and underscores
Autor:
Jamie L. Fantacone-Campbell, Darrell L. Ellsworth, Jamie D. Weyandt, Brenda Deyarmin, Craig D. Shriver, Rachel E. Ellsworth, Jeffrey A. Hooke
Publikováno v:
Annals of Surgical Oncology. 17:1688-1694
Columnar cell lesions (CCL) and atypical ductal hyperplasia (ADH) frequently coexist and share molecular changes with in situ and invasive components, suggesting that CCL and ADH may be precursors to breast cancer. These conclusions are largely based
Autor:
Christopher M. Counter, Benjamin L. Lampson, Sherry Tang, Jamie D. Weyandt, Diana M. Cardona, Matthew Mastrodomenico
Publikováno v:
PLoS ONE
PLoS ONE, Vol 10, Iss 10, p e0140253 (2015)
PLoS ONE, Vol 10, Iss 10, p e0140253 (2015)
Oncogenic, activating mutations in KRAS initiate pancreatic cancer. There are, however, two other Ras family members, Nras and Hras, which can be activated in the presence of oncogenic Kras. The role of these wild-type Ras proteins in cancer remains
Autor:
Jamie D. Weyandt
Publikováno v:
Redox Biology, Vol 5, Iss, Pp 414-(2015)
Background The RAS family of small GTPases is comprised of HRAS , NRAS, and KRAS. KRAS is invariably oncogenically mutated in pancreatic cancers, which is known to induce this disease. Beyond oncogenic KRAS, redox-dependent reactions have been implic
Autor:
Ryan van Laar, Darrell L. Ellsworth, Gera L. Jellema, Marina N. Vernalis, Jamie D. Weyandt, Mary Jane Haberkorn, Yaqin Chen, Lori A. Sturtz, Amy Burke, Kimberly A. Mamula, Daniel T. Croft, Fionnuala A. McDyer, Heather L. Blackburn
Publikováno v:
Circulation. Cardiovascular genetics. 7(2)
Background— Healthy lifestyle changes are thought to mediate cardiovascular disease risk through pathways affecting endothelial function and progression of atherosclerosis; however, the extent, persistence, and clinical significance of molecular ch